You are here

Article Text

Article menu
Download PDFPDF
PostScript
Letter
Recent initiatives to enhance the safety of intravenous medications in Chinese hospitals
  1. Shusen Sun
  1. Pharmacy Practice, Western New England University, Springfield, Massachusetts, USA
  1. Correspondence to Dr Shusen Sun, Pharmacy Practice, Western New England University, Springfield, MA 01119, USA; ssun{at}wne.edu

https://doi.org/10.1136/ejhpharm-2020-002412

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    According to the 2018 China National Adverse Drug Reaction (ADR) Monitoring Report, intravenous medications accounted for 60.0% of the reported ADRs.1 Over-reliance and improper administration of intravenous infusions are a severe health problem in China. A 2019 study reveals that 89.2% of patients received intravenous medications at a large Chinese academic hospital, and 11.4% of these prescriptions were inappropriate, ranging from improper diluents to contraindicated administrations.2 Over the past two decades, hospitals have been exploring ways to address intravenous medication safety in China. Efforts are focused on building hospital information systems and pharmacy intravenous admixture services (PIVAS), targeting the entire intravenous medication use process: prescribing, order …

    View Full Text

    Footnotes

    • Contributors SS: investigation, writing original draft.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests None declared.

    • Patient consent for publication Not required.

    • Provenance and peer review Not commissioned; internally peer reviewed.